Petauri, a leading purpose-built pharmaceutical services platform, announced today the addition of accomplished consultants Catherine Beecher and Sam Davies as Directors in Petauri Evidence, further strengthening the organization’s Global Pricing and Market Access (GPMA) team.
“It’s an exciting time for the business as we enhance our already exceptional team with proven leaders who bring deep pricing and market access knowledge, and real-world expertise in navigating the complex global landscape,” said David Niziol, President of Petauri Evidence. “Sam and Catherine join our expert team of pricing and market access consultants, led by Clare Foy and Adam Brown. The team collaborates with leading Pharmaceutical and Medical Device companies to develop pricing and market access strategies underpinned by evidence and payer insight, ensuring our clients are set up for success across global markets. This strategic growth, with the addition of Catherine and Sam, means we can deliver even greater expertise and experience—from early market landscaping through pricing and market access strategy, value proposition development, and launch readiness.”
Catherine Beecher joins Petauri with more than 25 years of global pricing and market access experience, having led strategic pricing, reimbursement, and access engagements across a broad portfolio of therapeutic areas. She brings a track record of working as a true partner with her clients to shape successful global pricing, market access, and evidence generation strategies—from early development through launch and lifecycle management.
Sam Davies joins Petauri with a substantial background in pricing, reimbursement, and access having led the Northern European hub for a leading pharmaceutical company supporting several therapeutic areas. In this role, Sam focused on leading the development of practical, evidence-based strategies to support market access across both public and private healthcare channels. His work has included shaping pricing approaches, supporting reimbursement submissions, and collaborating with regional and local stakeholders across therapeutic areas such as cardiometabolic health, immunology, and neuroscience.
This expansion of Petauri’s global strategic consulting services complements the organization’s US pricing and market access capabilities and further signifies their commitment to providing tailored support and innovative solutions that optimize value, drive access, and ultimately improve patient outcomes worldwide.
